Global Cannabis Pharmaceuticals Market, Global Cannabis Pharmaceuticals Market Report, Global Cannabis Pharmaceuticals Market Trends, Global Cannabis Pharmaceuticals Market Size

Global Cannabis Pharmaceuticals Market Trends and Growth Analysis 2025–2029

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Cannabis Pharmaceuticals Industry Compare Between 2025 And 2029?

The cannabis pharmaceuticals market has experienced substantial expansion in recent years. Its valuation is predicted to rise from $6.03 billion in 2024 to $9.43 billion in 2025, achieving a compound annual growth rate (CAGR) of 56.4%. Historically, this growth can be ascribed to several factors, including the increasing legalization of medical cannabis, greater public awareness of cannabinoid therapeutic benefits, a rise in chronic and neurological disorders, the implementation of supportive regulatory frameworks, expanding investments in pharmaceuticals, and an evolving public perception regarding cannabis use in healthcare.

The cannabis pharmaceuticals market size is forecast to experience significant growth in the coming years, projected to reach $55.53 billion by 2029, achieving a compound annual growth rate (CAGR) of 55.8%. This expansion during the forecast period is primarily driven by an increase in regulatory approvals, greater recognition of medical cannabis benefits, broader applications in the management of pain and neurological disorders, the rising incidence of chronic illnesses, innovations in drug delivery systems, and the implementation of supportive reimbursement policies. Noteworthy trends anticipated in this period encompass advancements in cannabinoid extraction technologies, the evolution of targeted drug delivery systems, the widespread adoption of synthetic cannabinoid formulations, refined clinical trial methodologies, and the integration of artificial intelligence for drug discovery.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

Which Drivers Are Impacting The Cannabis Pharmaceuticals Market?

The growing occurrence of epilepsy is projected to fuel the cannabis pharmaceuticals market in the future. Epilepsy is defined as a brain condition marked by repeated, spontaneous seizures, which result from unusual electrical patterns within the brain. The increase in epilepsy diagnoses stems from improved diagnostic methods, greater public awareness, and more comprehensive reporting, in addition to possible environmental, genetic, and lifestyle factors. Cannabis-based medicines offer a promising approach for epilepsy management, leveraging cannabinoids such as CBD to lessen the occurrence and intensity of seizures in individuals unresponsive to conventional anti-epileptic treatments. For example, data from April 2022, reported by the Belgium-based non-profit European Brain Council, indicates that over 600 neurological diseases and nearly 300 psychiatric conditions impact millions worldwide, with 65 million suffering from epilepsy. Furthermore, estimations from July 2024, provided by the Canada-based health charity Alzheimer Society of Canada, project that 771,939 Canadians will be living with dementia by January 1, 2025, a figure anticipated to climb to nearly one million by 2030. Consequently, the increased prevalence of epilepsy is propelling the expansion of the cannabis pharmaceuticals market.

What Are The Major Segment Types Covered In The Cannabis Pharmaceuticals Market?

The cannabis pharmaceuticalsmarket covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions

3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management

4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids

Which Competitive Trends Are Defining The Cannabis Pharmaceuticals Market Structure?

Major companies active in the cannabis pharmaceuticals market are concentrating on developing innovative products, such as advanced medical cannabis formulations, to address various medical conditions and improve patient outcomes. Advanced medical cannabis formulations refer to specially engineered cannabis-based products optimized for therapeutic purposes, incorporating precise doses of cannabinoids like THC and CBD. For instance, in April 2024, Canexis Pharma AG, a Switzerland-based pharmaceutical company, obtained manufacturing and narcotics licenses from Swissmedic for cannabis pharmaceuticals. These approvals enable the company to produce premium-grade medicinal active ingredients derived from CBD and THC. This development positions Canexis to satisfy the increasing demand for medical cannabis in both Switzerland and globally. By securing these licenses, the company demonstrates its compliance with stringent regulatory standards, enhancing its credibility and its ability to contribute to the rapidly evolving medical cannabis market.

Which Major Firms Are Strengthening Their Position In The Cannabis Pharmaceuticals Industry?

Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte’s Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

How Do Regional Market Performances Compare Within The Cannabis Pharmaceuticals Industry?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cannabis Pharmaceuticals Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Browse Through More Reports Similar to the Global Cannabis Pharmaceuticals Market 2025, By The Business Research Company

Cannabis Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-products-global-market-report

Cannabis Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

Cannabis Cultivation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-cultivation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795